ライフサイエンスコーパス: cholesterol absorption

1 pression of intestinal NPC1L1 expression and cholesterol absorption.

2 cholesterol transport and reduces intestinal cholesterol absorption.

3 erstanding EZE inhibition of NPC1L1-mediated cholesterol absorption.

4 ced by PX20606 was independent of changes in cholesterol absorption.

5 olesterol absorption than in those with high cholesterol absorption.

6 lowering drug that blocks intestinal dietary cholesterol absorption.

7 lesterol gallstones by inhibiting intestinal cholesterol absorption.

8 contributes to the regulation of intestinal cholesterol absorption.

9 mann-Pick C1-like 1 (NPC1L1) is required for cholesterol absorption.

10 es plasma cholesterol by blocking intestinal cholesterol absorption.

11 dly emerged as a key regulator of intestinal cholesterol absorption.

12 1L1), a gene that is required for intestinal cholesterol absorption.

13 rophilic bile salt pool decreased intestinal cholesterol absorption.

14 mibe, suggesting a possible role for CAV1 in cholesterol absorption.

15 enterocytes that is critical for intestinal cholesterol absorption.

16 sensitive pathway responsible for intestinal cholesterol absorption.

17 olesterol that act in the intestine to lower cholesterol absorption.

18 h studies is a possible role for the gene in cholesterol absorption.

19 olesterol secretion, but inhibits intestinal cholesterol absorption.

20 glyceride is necessary for efficient dietary cholesterol absorption.

21 lipoprotein synthesis, and (iii) intestinal cholesterol absorption.

22 level, bile acid composition, and intestinal cholesterol absorption.

23 ted with substantial decreases in intestinal cholesterol absorption.

24 -cell formation, and for ACAT2 in intestinal cholesterol absorption.

25 nally thought to be its mediation of dietary cholesterol absorption.

26 to participate in the regulation of dietary cholesterol absorption.

27 novel pharmacological approaches to inhibit cholesterol absorption.

28 es correlated with the percentage of dietary cholesterol absorption.

29 o the bile and suppressed percentage dietary cholesterol absorption.

30 ers but does not play a primary role in free cholesterol absorption.

31 gradation, while ezetimibe limits intestinal cholesterol absorption.

32 c enzymes, tissue BA levels and triglyceride/cholesterol absorption.

33 r knockdown of NPC1L1 attenuated CCK-induced cholesterol absorption.

34 ed CCK-induced NPC1L1-Rab11a interaction and cholesterol absorption.

35 intracellular cholesterol transporter 1) and cholesterol absorption.

36 CK2R with antagonists attenuated CCK-induced cholesterol absorption.

37 pressed CCK-induced NPC1L1 translocation and cholesterol absorption.

38 ol loss, compatible with enhanced intestinal cholesterol absorption.

39 D19H of ABCG8 are associated with diminished cholesterol absorption.

40 rol levels that equally represent markers of cholesterol absorption.

41 s accelerated RCT by compromising intestinal cholesterol absorption.

42 Both ezetimibe and phytosterols inhibit cholesterol absorption.

43 erol secretion without increasing intestinal cholesterol absorption.

44 pectively) and reduced percentage intestinal cholesterol absorption (-10 +/- 1% and -25 +/- 3%, respe

45 eight), a more efficient level of intestinal cholesterol absorption (41.1% vs. 25.3%), and a lower ra

46 t resulted in significantly lower intestinal cholesterol absorption (598 mg/d; 95% confidence interva

47 reatment significantly increased (P = 0.013) cholesterol absorption (72.6% +/- 2.9%) compared with di

48 as identified to be essential for intestinal cholesterol absorption, a process that is sensitive to a

49 synthesis in liver, and inhibits intestinal cholesterol absorption, actions that would collectively

50 stinal lumen is a prerequisite for efficient cholesterol absorption, additional enzyme(s) can compens

51 ariations identified in individuals with low cholesterol absorption affect protein function, we perfo

52 ciency results in a significant reduction in cholesterol absorption, although other enzymes in the di

53 menal bile with CA results in an increase in cholesterol absorption, an effect potentially mediated b

54 C1-Like 1 (NPC1L1) as a critical mediator of cholesterol absorption and an essential component of the

55 a high-fat diet (HFD), PA reduced intestinal cholesterol absorption and aortic atherosclerotic lesion

56 Aster-deficient mice have impaired cholesterol absorption and are protected against diet-in

57 rotein E (apoE) in the regulation of dietary cholesterol absorption and biliary cholesterol excretion

58 allstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion

59 Thereafter, cholesterol absorption and cholesterol fractional synthe

60 In the present study, we showed that dietary cholesterol absorption and commensal recognition by duod

61 ntial for jejunal function including fat and cholesterol absorption and confirm that GATA4 plays a pi

62 s a sterol transporter to mediate intestinal cholesterol absorption and counter-balances hepatobiliar

63 ring medications (n = 114), plasma surrogate cholesterol absorption and endogenous synthesis biomarke

64 olesterol profile or surrogate biomarkers of cholesterol absorption and endogenous synthesis.

65 es by measuring plasma sterols as indexes of cholesterol absorption and endogenous synthesis.

66 Fractional cholesterol absorption and fecal neutral sterol excretio

67 Plasma markers of cholesterol absorption and hepatic cholesterol metabolis

68 s cholelithogenesis by promoting gallbladder cholesterol absorption and impairing gallbladder motilit

69 ficant suppression of the percentage dietary cholesterol absorption and increased gallbladder biliary

70 ty has been observed for rates of intestinal cholesterol absorption and LDL-C reductions at both base

71 ith large quantities of phytosterols reduces cholesterol absorption and LDL-cholesterol concentration

72 ore throw light on regulation of net dietary cholesterol absorption and lead to an advancement in the

73 respond have been identified as having high cholesterol absorption and low cholesterol biosynthesis.

74 (phytosterols) and the drug ezetimibe reduce cholesterol absorption and low-density lipoprotein chole

75 absorption inhibitor, ezetimibe, normalized cholesterol absorption and low-density lipoprotein chole

76 Plant sterol esters reduce cholesterol absorption and lower circulating blood chole

77 Ezetimibe inhibits intestinal cholesterol absorption and lowers low-density lipoprotei

78 of commercial corn oil substantially reduced cholesterol absorption and may account for part of the c

79 esis and plays a critical role in intestinal cholesterol absorption and pathogenesis of cholesterol g

80 any putative sterol transporters influencing cholesterol absorption and physical-chemical factors aff

81 tion in NPC1L1 contributes to variability in cholesterol absorption and plasma levels of low-density

82 cholesterol balance, including inhibition of cholesterol absorption and repressed bile acid synthesis

83 Studies of intestinal cholesterol absorption and reverse cholesterol transport

84 Gallbladder cholesterol absorption and size were significantly great

85 s a molecular pathway that regulates dietary cholesterol absorption and sterol excretion by the body.

86 xylated bile acids, which promote intestinal cholesterol absorption and suppress hepatic cholesterol

87 intralumenal bile acid composition may alter cholesterol absorption and synthesis and low-density lip

88 In parallel, we measured markers of cholesterol absorption and synthesis in humans with type

89 Cholesterol absorption and synthesis were assessed by us

90 testinal NPC1L1 transporter is essential for cholesterol absorption and the maintenance of cholestero

91 of other studies suggest that it facilitates cholesterol absorption and the transfer of cholesterol i

92 Through integrated regulation of cholesterol absorption and TICE, the small intestine is

93 assess the contribution of these pathways to cholesterol absorption and to determine whether there ar

94 The strong association between intestinal cholesterol absorption and total plasma cholesterol leve

95 stinal transit times (resulting in increased cholesterol absorption), and increased biliary cholester

96 oncentrations, a 25% reduction in fractional cholesterol absorption, and a 4-fold elevation in fecal

97 f genes that regulate macrophage chemotaxis, cholesterol absorption, and fatty acid binding.

98 cholesterol secretion, decreased fractional cholesterol absorption, and increased fecal neutral ster

99 tion reduced expression of NPC1L1, decreased cholesterol absorption, and increased levels of hydrophi

100 tanol and plant sterols provide a measure of cholesterol absorption, and lathosterol provides a measu

101 ed with abnormal immune function, intestinal cholesterol absorption, and lipid metabolism.

102 er, reduces 12alpha-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol levels.

103 ncreases in 12alpha-hydroxylated bile acids, cholesterol absorption, and plasma cholesterol.

104 We measured bile acid composition, cholesterol absorption, and plasma cholesterol.

105 Those with low cholesterol absorption appear to benefit from treatment

106 e was primarily due to diminished intestinal cholesterol absorption as the result of changes in the c

107 ansporters ABCG5/8 and NPC1L1 and intestinal cholesterol absorption as well as de novo synthesis in g

108 Intestinal cholesterol absorption, as reflected by cholestanol-to-c

109 = 60 mg/kg) as measured in an acute hamster cholesterol absorption assay.

110 rol excretion and the decrease in fractional cholesterol absorption associated with LXR agonist treat

111 Sitostanol reduced cholesterol absorption at doses lower than reported prev

112 ces atherosclerosis by increasing intestinal cholesterol absorption, augmenting uptake of modified li

113 sterol ratio (CR) was used as an estimate of cholesterol absorption because it is independent of plan

114 ), small-intestinal transit time, intestinal cholesterol absorption, biliary cholesterol secretion, a

115 a new class of drugs that inhibit intestinal cholesterol absorption, blocks SR-BI- and CD36-facilitat

116 Compared to controls, cholesterol absorption but not synthesis in gallstone ca

117 ioleoyl ether phosphatidylcholine suppressed cholesterol absorption by 10% to 18% in mice without reg

118 ast, sitostanol in lecithin micelles reduced cholesterol absorption by 36.7 +/- 4.2% (P = 0.003) at a

119 HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared wit

120 These data imply that CCK enhances cholesterol absorption by activation of a pathway involv

121 s indicate that phospholipase A2 may mediate cholesterol absorption by altering the physical-chemical

122 d hypercholesterolemia; increased intestinal cholesterol absorption by hydrophobic bile acids might c

123 Activation of FXR inhibits intestinal cholesterol absorption by modulation of bile acid pool s

124 Sitostanol powder (1 g) reduced cholesterol absorption by only 11.3 +/- 7.4% (P = 0.2),

125 s respond to the pharmacological blockade of cholesterol absorption by ramping up de novo sterol synt

126 derstanding about the mechanisms involved in cholesterol absorption by the intestinal cells.

127 sterol O-acyl transferase 2 (ACAT2) promotes cholesterol absorption by the intestine and the secretio

128 Physiological studies showed that enhanced cholesterol absorption by the intestine contributes to h

129 ncreatic secretion is required for efficient cholesterol absorption by the intestine, but the factors

130 However, reduction of cholesterol absorption can be measured at a dose of only

131 be, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovas

132 in an amount sufficient to block intestinal cholesterol absorption caused small intestinal transit t

133 ere given FGF19 daily for 1 week; fractional cholesterol absorption, cholesterol and bile acid (BA) l

134 s represent surrogate markers for intestinal cholesterol absorption, cholesterol precursors reflect c

135 e had a nearly 2-fold increase in intestinal cholesterol absorption compared with controls.

136 etary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol

137 ts showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formatio

138 Although NPC1L1 is required for intestinal cholesterol absorption, data demonstrating mechanisms by

139 Cholesterol absorption decreased as a result of PS consu

140 Intestinal cholesterol absorption decreases from 54 to 4% in knocko

141 Cholesterol absorption efficiency decreased (P = 0.010)

142 Under basal chow-fed dietary conditions, cholesterol absorption efficiency from a single bolus me

143 Cholesterol absorption efficiency was determined by feca

144 expression of an array of genes involved in cholesterol absorption, efflux, transport, and excretion

145 However, the LXR agonist T0901317 decreased cholesterol absorption equally in both wild type and WHA

146 ed steatorrhea, growth arrest, and decreased cholesterol absorption, features that collectively recap

147 Primary outcomes were intestinal cholesterol absorption, fecal cholesterol excretion, and

148 ever, it did not alter fractional intestinal cholesterol absorption, fecal neutral sterol excretion,

149 sterol (PPS) levels, a surrogate measure of cholesterol absorption from the intestine, where previou

150 Gallbladder motility and cholesterol absorption, gallstones and expression of the

151 Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout

152 SCH 48461), a novel inhibitor of intestinal cholesterol absorption, has recently been described by B

153 physical-chemical factors affecting dietary cholesterol absorption have been extensively investigate

154 s, used as dietary complement for decreasing cholesterol absorption, have been synthesized at 28 degr

155 e and liver, which in turn limits intestinal cholesterol absorption, hepatic cholesterol gallstone fo

156 physiologic processes, including intestinal cholesterol absorption, hepatic lipoprotein production,

157 ing cholesterol is the balance among dietary cholesterol absorption, hepatic synthesis and secretion,

158 The PLA2 inhibitor FPL 67047XX retarded cholesterol absorption in a lymph fistula rat model.

159 rol precursor) was used to estimate relative cholesterol absorption in a population-based study.

160 sed plasma cholesterol levels and intestinal cholesterol absorption in both wild-type and LDLR(-/-) m

161 ezetimibe is equally effective in decreasing cholesterol absorption in Cav1 null mice and wild-type c

162 d in Cyp7a1-tg mice but intestine fractional cholesterol absorption in Cyp7a1-tg mice remained the sa

163 The role of cholic acid (CA) in cholesterol absorption in humans remains unclear and, th

164 l tissues, bile acid synthesis in liver, and cholesterol absorption in intestine.

165 nges occurred despite a relative decrease in cholesterol absorption in LD-fed Apobec-1(-/-) mice.

166 zing phospholipid digestion and facilitating cholesterol absorption in PLA2 knockout mice.

167 Over this range, fractional cholesterol absorption in the ACAT2(+/+) mice fell from

168 Human NPC1L1 protein mediates cholesterol absorption in the intestine and liver and is

169 By contrast, ACAT2 -/- mice have limited cholesterol absorption in the intestine, and decreased c

170 Modulation of cholesterol absorption in the intestine, the primary sit

171 Ezetimibe potently and selectively inhibits cholesterol absorption in the intestine, thereby reducin

172 f [(14) C]cholesterol in lymph by inhibiting cholesterol absorption in the OVX rats.

173 -BI may be involved but is not essential for cholesterol absorption in the small intestine.

174 The question of whether SR-BI contributes to cholesterol absorption in vivo is still unresolved.

175 tedly, empagliflozin also reduced intestinal cholesterol absorption in vivo, which led to a significa

176 ss this issue, we measured beta-carotene and cholesterol absorption in wild-type and SR-BI knockout m

177 absence of changes in fractional intestinal cholesterol absorption, increased secretion of sterols i

178 in the setting of relatively low intestinal cholesterol absorption, indicating enhanced whole-body s

179 ter and the molecular target of ezetimibe, a cholesterol absorption inhibitor demonstrated to reduce

180 ike protein (NPC1L1) and is sensitive to the cholesterol absorption inhibitor ezetimibe (EZE).

181 ne formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent

182 The cholesterol absorption inhibitor ezetimibe may offer a v

183 in enterocytes that can be disrupted by the cholesterol absorption inhibitor ezetimibe, suggesting a

184 absorption, a process that is sensitive to a cholesterol absorption inhibitor ezetimibe.

185 the FXR agonist PX20606, with or without the cholesterol absorption inhibitor ezetimibe.

186 to those of wild type mice treated with the cholesterol absorption inhibitor ezetimibe.

187 the last LDL-cholesterol-lowering drug, the cholesterol absorption inhibitor ezetimibe.

188 PC1L1 appears to be a target of ezetimibe, a cholesterol absorption inhibitor that effectively lowers

189 the molecular target of ezetimibe, a potent cholesterol absorption inhibitor that is widely used in

190 -dependently inhibited by ezetimibe, a novel cholesterol absorption inhibitor that specifically binds

191 In parallel, the cholesterol absorption inhibitor, ezetimibe, normalized

192 ogether with the discovery of a new class of cholesterol absorption inhibitor, has yielded new insigh

193 The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has

194 Ezetimibe (1), a strong beta-lactamic cholesterol absorption inhibitor, was synthesized from (

195 Ezetimibe is a selective cholesterol absorption inhibitor, with a site of action

196 ive preparation of Ezetimibe, the commercial cholesterol absorption inhibitor.

197 the intestine, a process that is blocked by cholesterol absorption inhibitors (CAIs), including ezet

198 own about intestinal sterol transporters and cholesterol absorption inhibitors (CAIs).

199 o be larger among patients taking statins or cholesterol absorption inhibitors at baseline (mean trea

200 A series of azetidinone cholesterol absorption inhibitors related to SCH 48461 (

201 explored the use of steroidal glycosides as cholesterol absorption inhibitors which act through an u

202 ms to further probe the SAR of 2-azetidinone cholesterol absorption inhibitors.

203 1' position provided compounds with improved cholesterol absorption inhibitory activity.

204 Cholesterol absorption is a key regulatory point in huma

205 These findings indicate that cholesterol absorption is a multistep process that is re

206 Cholesterol absorption is a selective process in that pl

207 The inhibition of cholesterol absorption is an important therapeutic strat

208 High cholesterol absorption is associated with risk alleles i

209 Increasingly, new studies suggest that cholesterol absorption is genetically controlled and sup

210 icating that the effect of LXR activation on cholesterol absorption is independent of ABCA1.

211 The mechanism of cholesterol absorption is not completely known but invol

212 r mechanism by which these compounds inhibit cholesterol absorption is unknown.

213 tral sterol secretion and reduces intestinal cholesterol absorption, leading to a selective increase

214 In two extended families, mean cholesterol absorption levels, as measured using stable

215 and whole-body sterol homeostasis, including cholesterol absorption, lipoprotein synthesis and remode

216 erol/cholesterol and sitosterol/cholesterol (cholesterol absorption markers) had decreasing order in

217 enterocyte level and that the efficiency of cholesterol absorption may be determined by the net effe

218 ze that ezetimibe, which inhibits intestinal cholesterol absorption, may not exert similar cholestero

219 e fecal cholesterol excretion and intestinal cholesterol absorption measured with stable-isotope trac

220 To determine fractional cholesterol absorption, mice were given intravenous inje

221 mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinicall

222 had significantly lower levels of intestinal cholesterol absorption, more fecal sterol excretion, and

223 Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) an

224 udies suggest that, when soy protein is fed, cholesterol absorption or bile acid reabsorption, or bot

225 ignificant effect on surrogate biomarkers of cholesterol absorption or endogenous synthesis, consiste

226 ts demonstrate that CAV1 is not required for cholesterol absorption or ezetimibe sensitivity in the m

227 ffect biliary cholesterol levels, fractional cholesterol absorption, or neutral fecal sterol excretio

228 at 24 weeks of age showed a 27% decrease in cholesterol absorption (P < .001) and reduced levels of

229 (ABCG5/ABCG8), which affects the intestinal cholesterol absorption pathway targeted by BAS and then

230 ys a crucial role in the ezetimibe-sensitive cholesterol absorption pathway.

231 oprotein B (apoB)-dependent and -independent cholesterol absorption pathways and the role of microsom

232 tte transporter A1 gene regulates intestinal cholesterol absorption, perhaps by mediating cholesterol

233 Measurements of serum surrogate markers of cholesterol absorption (plant sterols: sitosterol, campe

234 ed hepatic cholesterol uptake and intestinal cholesterol absorption play an essential role in LXR-pro

235 rsely correlated with the percentage dietary cholesterol absorption (r = -0.63, P < 0.0001).

236 sought to investigate whether the individual cholesterol absorption rate affects atorvastatin's effec

237 Harm caused by elevated cholesterol absorption rather than by plant sterols may

238 The most pronounced effect on cholesterol absorption ratio was observed for serum camp

239 er treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in p

240 esterol transporter essential for intestinal cholesterol absorption, reduces the output of dry stool

241 sought to determine whether high intestinal cholesterol absorption represents a cardiovascular risk

242 Intestinal cholesterol absorption represents a major route for the

243 Cholesterol absorption results were similar between the

244 ctive products against pancreatic lipase and cholesterol absorption simultaneously.

245 Analyzing the data on the basis of cholesterol absorption status (hypo- versus hyperabsorbe

246 We determined whether differences in cholesterol absorption, synthesis, or both could be resp

247 atic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic

248 antly more common among individuals with low cholesterol absorption than in those with high cholester

249 Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the tr

250 conclusion, although ACAT2 deficiency limits cholesterol absorption, the extent to which it impacts h

251 icate that upregulation of the gene inhibits cholesterol absorption, the results of other studies sug

252 LXR) agonists have been inferred to decrease cholesterol absorption through activation of ABCA1 expre

253 suggested phospholipid inhibition of dietary cholesterol absorption through the gastrointestinal trac

254 ol esterase (bile salt-stimulated lipase) in cholesterol absorption through the intestine has been co

255 or either one of them diminished CCK-induced cholesterol absorption to the same extent.

256 Ezetimibe interacts with the intestinal cholesterol absorption transporter NPC1l1 to block chole

257 obtained throughout the study with tests of cholesterol absorption undertaken at baseline and end of

258 ) on plasma cholesterol level and intestinal cholesterol absorption using the in vivo models of C57BL

259 Cholesterol absorption was 38.0 +/- 10.2% higher after c

260 Cholesterol absorption was 41% lower in PTL(-/-) mice co

261 Cholesterol absorption was about 24% lower in individual

262 The regulation of dietary cholesterol absorption was examined in C57BL/6 and trans

263 Cholesterol absorption was highest in the LIS participan

264 including NPC1L1, were up-regulated and that cholesterol absorption was increased in SHP-knockout mic

265 The ability of sitostanol to reduce cholesterol absorption was measured directly by includin

266 oil at a concentration of 150 mg/test meal, cholesterol absorption was reduced by 12.1 +/- 3.7% (P =

267 Acute cholesterol absorption was reduced by 28% in the absence

268 on was increased only 3-fold, and intestinal cholesterol absorption was reduced only 20%, indicating

269 We found that cholesterol absorption was significantly decreased as a

270 Pharmacological blockade of cholesterol absorption was unable to further induce the

271 CA1, previously implicated in the control of cholesterol absorption, was also dramatically up-regulat

272 Cholesterol synthesis and change in cholesterol absorption were measured with stable isotopi

273 ratio, which is an established biomarker of cholesterol absorption, were used to identify high and l

274 fter emulsification with lecithin and reduce cholesterol absorption when added to nonfat foods.

275 sterifies absorbed cholesterol and increases cholesterol absorption when dietary intake is high.

276 ng phytosterols from corn oil would increase cholesterol absorption when measured in single-meal test

277 al cells with [Thr(28),Nle(31)]CCK increased cholesterol absorption, whereas selective inhibition of

278 , a novel, potent and selective inhibitor of cholesterol absorption which is effective in milligram d

279 ingly, empagliflozin also reduces intestinal cholesterol absorption, which in turn promotes LDL- and

280 Inhibition of intestinal cholesterol absorption with ezetimibe promotes antiather